Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...

adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukaemia. Kymriah was the first CAR-T to reach the market in 2017, but was closely followed by ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

In August 2022, T-Mobile and SpaceX announced a bold plan to expand cellular connectivity across the US with the help of low-orbit satellites. Fast-forward to 2025, and the T-Mobile Starlink ...

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

Many cells in multicellular organisms are specialised. They have specific roles in the organism of which they are part. Their structure is adapted to their function. They are often grouped ...